Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in plaque psoriasis (ACD2601g)
NCT00096603Phase 3Completed
- Sponsor
- Genentech
- Start
- Oct 2002
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of efalizumab in plaque psoriasis, sponsored by Genentech. Primary endpoint: Incidence of Adverse Events. Started Oct 2002; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00096603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096603.